Top News in R&D





 Global Health Technologies Coalition 


R&D News Roundup: November 6, 2023


Top News in R&D

New gonorrhoea treatment shows positive results in trial sponsored by non-profit partnership
Health Policy Watch (11/2), features the Global Antibiotic Research & Development Partnership

Last Wednesday, the Global Antibiotic Research and Development Partnership (GARDP) announced the results of a successful phase 3 trial, conducted in collaboration with Innoviva Specialty Therapeutics and supported by the National Institute of Allergy and Infectious Diseases, which found that a single dose of a first-in-class oral antibiotic, zoliflodacin, was as safe and effective as standard therapy for treating uncomplicated urogenital gonorrhea. The growing resistance of the gonorrhea bacteria to many classes of antibiotics has left only one remaining globally recommended treatment available as an option. Zoliflodacin, if approved, could not only help address those rising cases because studies have shown that it is active against multi-drug resistant gonorrhea strains, but the antibiotic will also simplify treatment because it is one pill rather than an injection and a pill like the current standard therapy.

CEPI, Oxford launch project to develop arenavirus vaccines
CIDRAP (11/2), features the Coalition for Epidemic Preparedness Innovations (CEPI)

Last week, the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford announced the launch of a new project to develop prototype vaccines against an arenavirus called Junin virus, which causes Argentine hemorrhagic fever. The project is aimed at kickstarting the broader development of vaccines for arenaviruses, which include the virus that causes Lassa fever, one of CEPI’s priority pathogens. CEPI will invest $25 million in the development of early prototypes of viral vector and mRNA vaccines against the Junin virus, as well as the improvement of the ChAdOx viral vector technology, part of the broader partnership between CEPI and Oxford to support vaccine development for a variety of viral families with future epidemic or pandemic potential.

New study shows how the Ebola virus infects cells (11/1)

In a recent study, researchers have identified a new molecule in cells that is necessary for the Ebola and Marburg viruses to infect and spread in the body and that is also involved in SARS-CoV-2 infections. This discovery could eventually lead to new antiviral drugs for Ebola and Marburg, among other viral infections. The molecular, CCZ1, is a protein that regulates the transport of other molecules by cells. Researchers from the Karolinska Institutet and Institute of Molecular Biotechnology used advanced stem cell libraries and lab-grown organs to study how viruses infect the human liver and blood vessels and ultimately demonstrate how CCZ1 operates as a key factor in their spread through the body.



News from GHTC

Brazil once pioneered generic drugs, and then came a patent war
Bloomberg (11/3), features Medicines Patent Pool

A 'tropical disease' carried by sand flies is confirmed in a new country: the U.S.
NPR (11/1), features the American Society of Tropical Medicine & Hygeiene

A chikungunya vaccine is nearing approval. Who will get it?
Science (10/30), features CEPI and Valneva

Opinion: Time to tackle AMR together
Nature (10/30), features the Combating Antibiotic Resistant Bacteria Biopharmaceutial Accelerator



Highlights From the Week



COVID-19 R&D Roundup



Upcoming Events